Analysts’ Weekly Ratings Changes for Marinus Pharmaceuticals (MRNS)

Several analysts have recently updated their ratings and price targets for Marinus Pharmaceuticals (NASDAQ: MRNS):

• 9/23/2024 – Marinus Pharmaceuticals was upgraded by analysts at Oppenheimer Holdings Inc. from a “market perform” rating to an “outperform” rating. They now have a $6.00 price target on the stock.
• 9/18/2024 – Marinus Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 9/16/2024 – Marinus Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $13.00 price target on the stock.
• 9/9/2024 – Marinus Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $13.00 price target on the stock.
• 9/9/2024 – Marinus Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 8/22/2024 – Marinus Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 8/14/2024 – Marinus Pharmaceuticals was downgraded by analysts at LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating.
• 8/14/2024 – Marinus Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 8/14/2024 – Marinus Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.

Marinus Pharmaceuticals Trading Up 3.7 %

Shares of MRNS stock opened at $1.66 on Monday. The company has a quick ratio of 2.15, a current ratio of 2.28 and a debt-to-equity ratio of 5.68. The firm has a market cap of $91.19 million, a P/E ratio of -0.63 and a beta of 1.13. The company has a 50 day moving average of $1.38 and a 200-day moving average of $2.78. Marinus Pharmaceuticals, Inc. has a 12-month low of $1.05 and a 12-month high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The firm had revenue of $8.06 million during the quarter, compared to the consensus estimate of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same quarter in the prior year, the firm posted ($0.61) earnings per share. Sell-side analysts anticipate that Marinus Pharmaceuticals, Inc. will post -1.88 earnings per share for the current year.

Institutional Trading of Marinus Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC lifted its stake in Marinus Pharmaceuticals by 31.4% in the 1st quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock worth $37,431,000 after purchasing an additional 990,607 shares in the last quarter. Franklin Resources Inc. increased its stake in Marinus Pharmaceuticals by 1.3% in the fourth quarter. Franklin Resources Inc. now owns 3,833,955 shares of the biopharmaceutical company’s stock valued at $41,675,000 after acquiring an additional 49,589 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Marinus Pharmaceuticals by 5.0% in the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after purchasing an additional 132,689 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Marinus Pharmaceuticals in the second quarter worth approximately $813,000. Finally, Renaissance Technologies LLC bought a new position in Marinus Pharmaceuticals during the second quarter valued at approximately $727,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.